New pill for psoriasis tested in everyday clinics
NCT ID NCT07256015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 Italian patients with moderate-to-severe psoriasis who are already taking deucravacitinib, a daily pill that calms the immune system. Researchers will track how well the drug controls skin symptoms, its side effects, and how it affects quality of life in real-world settings. The goal is to see if the benefits seen in clinical trials hold up outside of controlled research environments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Azienda Ospedaliera Universitaria Integrata Di Verona
RECRUITINGVerona, Verona, 37126, Italy
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Deucravacitinib (a pill that targets inflammation)
What this could lead to
If successful, this study could confirm that deucravacitinib works well in everyday clinical practice for people with moderate-to-severe psoriasis, offering a convenient oral treatment option.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already on the drug, and long-term safety or effectiveness beyond the study period is not assessed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.